Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PegInterferon Clear all
Completed Phase 2 Interventional Results available

A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

NCT00720434
View directory record Official record
Conditions
Hepatitis C
Interventions
PF-00868554, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
La Jolla, California • San Francisco, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2013 · Synced Sep 21, 2026, 10:35 PM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

NCT05070364
View directory record Official record
Conditions
Hepatitis Delta Virus
Interventions
Peginterferon Lambda-1a
Drug
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Los Angeles, California • Redwood City, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers

NCT01610310
View directory record Official record
Conditions
Healthy, Multiple Sclerosis
Interventions
BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS), BIIB017 (peginterferon beta-1a) Autoinjector
Device
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Sep 21, 2026, 10:35 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

NCT06144697
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986465, Placebo, Pegasys, Famotidine
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Anaheim, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy

NCT00087646
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
948 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
36
States / cities
Mobile, Alabama • Scottsdale, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

NCT01054729
View directory record Official record
Conditions
Hepatitis C
Interventions
Sofosbuvir, Placebo, PEG, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

NCT02269930
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
peginterferon beta-1a, Rebif
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Results available

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

NCT00087607
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, Peginterferon alfa-2b (PEG-Intron), Peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 3 Interventional

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00040027
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
46
States / cities
Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 3 Interventional

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

NCT00050531
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic
Interventions
Gleevec, Peg-alpha interferon (Peg-Intron), Sargramostim (GM-CSF)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

NCT00665353
View directory record Official record
Conditions
HIV-1 and Hepatitis C Co-Infection
Interventions
pioglitazone, peginterferon, ribavirin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1

NCT00249574
View directory record Official record
Conditions
Hepatitis C, Heroin Dependence
Interventions
Buprenorphine/naloxone, pegInterferon
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

NCT00703118
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Tibotec BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2014 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

NCT00535847
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated interferon alfa 2a
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

NCT01479868
View directory record Official record
Conditions
Hepatitis C Virus Genotype-1
Interventions
TMC435, Pegylated interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional

PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery

NCT00276523
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
PEG-interferon alfa-2b, Conventional surgery, Neoadjuvant therapy
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional

Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

NCT00502788
View directory record Official record
Conditions
Hepatitis C, Thalassemia
Interventions
Peginterferon Alfa-2a and Ribavirin, Ribavirin
Drug
Lead sponsor
Carelon Research
Other
Eligibility
18 Years to 44 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Oakland, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C

NCT00495391
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Nitazoxanide, Placebo, Peginterferon alfa-2a, Ribavirin
Drug · Biological
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
Palo Alto, California • Stanford, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

NCT01795911
View directory record Official record
Conditions
Hepatitis C
Interventions
Pegylated Interferon Lambda, Ribasphere, Daclatasvir
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 21, 2026, 10:35 PM EDT
Terminated Phase 4 Interventional Results available

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

NCT01467492
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 21, 2026, 10:35 PM EDT
Recruiting Phase 1Phase 2 Interventional

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

NCT07288112
View directory record Official record
Conditions
Refractory Melanoma
Interventions
DOC1021, Tumor resection, pIFN (peginterferon alfa-2a)
Biological · Procedure · Drug
Lead sponsor
Diakonos Oncology Corporation
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
8
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

NCT01625338
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF, RBV, Peg-IFN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
67
States / cities
Birmingham, Alabama • Bakersfield, California • Colton, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2015 · Synced Sep 21, 2026, 10:35 PM EDT
Terminated Phase 1Phase 2 Interventional

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

NCT00085384
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
PEG-interferon alfa-2b, PEG-interferon alfa-2b
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 21, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Study of PEG-Intron for Plexiform Neurofibromas

NCT00396019
View directory record Official record
Conditions
Plexiform Neurofibroma
Interventions
PEG-Intron
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Months to 21 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 21, 2026, 10:35 PM EDT